"The U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma. This is the first product in its class (PD-1/PD-L1 inhibitors) approved to treat this type"...
No adverse events were reported in a dose-finding study conducted among patients whose bladders were instilled with twice the recommended concentration (dose) of solution of Cysview (hexaminolevulinate hydrochloride intravesical solution) .
Cysview (hexaminolevulinate hydrochloride intravesical solution) is contraindicated in patients with:
- gross hematuria
- BCG immunotherapy or intravesical chemotherapy within the past 90 days
- known hypersensitivity to hexaminolevulinate or any derivative of aminolevulinic acid
Last reviewed on RxList: 6/29/2010
Additional Cysview Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.